Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062127 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00062127: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00062127 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062127, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with irinotecan may kill more tumor cells. This randomized phase I trial is studying the side effects and best way to give irinotecan and thalidomide in treating patients with metastatic or unresectable solid tumors
Interventions
- OTHER pharmacological study
- DRUG irinotecan hydrochloride
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062127
The ClinicalTrials.gov registry entry for NCT00062127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00062127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062127 about?
NCT00062127 is a clinical study titled "Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors". Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with irinotecan may kill more tumor cells. This randomized phase I tria...
What is the current status of trial NCT00062127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2003-04.
What interventions are being tested in trial NCT00062127?
The interventions under investigation include: pharmacological study (OTHER), irinotecan hydrochloride (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00062127?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.